{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:26Z","timestamp":1780586066546,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01723-z","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:27:30Z","timestamp":1776346050000},"page":"2919-2929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4\u00a0mg in Severe Alopecia Areata: Evidence-based Approach"],"prefix":"10.1007","volume":"16","author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jedynak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-9689","authenticated-orcid":false,"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"4","key":"1723_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with Alopecia Areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"1723_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of Baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"10387","key":"1723_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with Alopecia Areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"5","key":"1723_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with Alopecia Areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1723_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5782827","volume":"2024","author":"S Deng","year":"2024","unstructured":"Deng S, Wang H, Fu J, Zhai Z, Chen Q, Song Z. An observational study of early treatment response and predictors of Dupilumab in the treatment of moderate-to-severe Atopic Dermatitis. Dermatol Ther. 2024;2024(1):5782827.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1723_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jdv.20547","volume":"39","author":"B King","year":"2025","unstructured":"King B, Mirmirani P, Lo Sicco K, Ramot Y, Sinclair R, Asfour L, et al. Patterns of clinical response in patients with Alopecia Areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1723_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, Egeberg A, Piraccini BM, Craiglow B, et al. When to expect scalp hair regrowth during treatment of severe Alopecia Areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666\u201373.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1723_CR8","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1007\/s13555-023-01033-8","volume":"13","author":"S Taylor","year":"2023","unstructured":"Taylor S, Korman NJ, Tsai T-F, Shimomura Y, Feely M, Dutronc Y, et al. Efficacy of Baricitinib in patients with various degrees of Alopecia Areata severity: post hoc analysis from BRAVE AA1 and BRAVE AA2. Dermatol Ther. 2023;13(12):3181\u201391.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1723_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of Baricitinib in patients with severe Alopecia Areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"key":"1723_CR10","doi-asserted-by":"crossref","unstructured":"Mostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, et al. Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow\/eyelash regrowth in the first year. J Eur Acad Dermatol Venereol. 2024.","DOI":"10.1111\/jdv.20334"},{"issue":"2","key":"1723_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in Alopecia Areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1723_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1723_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in Alopecia Areata. Am J Clin Dermatol. 2020;21(5):725\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1723_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/jdv.20526","volume":"39","author":"C Tziotzios","year":"2025","unstructured":"Tziotzios C, Sinclair R, Lesiak A, Mehlis S, Kinoshita\u2010Ise M, Tsianakas A, et al. Long\u2010term safety and efficacy of ritlecitinib in adults and adolescents with Alopecia Areata and at least 25% scalp hair loss: results from the ALLEGRO\u2010LT phase 3, open\u2010label study. J Eur Acad Dermatol Venereol. 2025;39(6):1152\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1723_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/ijt.ijt_28_21","volume":"15","author":"K Malhotra","year":"2023","unstructured":"Malhotra K, Madke B. An updated review on current treatment of Alopecia Areata and newer therapeutic options. Int J Trichol. 2023;15(1):3\u201312.","journal-title":"Int J Trichol"},{"issue":"1","key":"1723_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","volume":"80","author":"K Phan","year":"2019","unstructured":"Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for Alopecia Areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(1):120-7.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1723_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jaad.2025.03.085","volume":"93","author":"K Valido","year":"2025","unstructured":"Valido K, Craiglow BG. Baricitinib and oral minoxidil for the treatment of Alopecia Areata in pediatric patients. J Am Acad Dermatol. 2025;93(2):509\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1723_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ajd.14325","volume":"65","author":"W Cranwell","year":"2024","unstructured":"Cranwell W, Meah N, Wall D, Bhoyrul B, Laita B, Sinclair RD. Real-world effectiveness and safety of tofacitinib for Alopecia Areata: a retrospective cohort study of 202 patients. Austral J Dermatol. 2024;65(6):505\u201313.","journal-title":"Austral J Dermatol"},{"key":"1723_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jdcr.2022.08.037","volume":"29","author":"R Talty","year":"2022","unstructured":"Talty R, Damsky W, King B. Sisaipho Alopecia Areata treated with tofacitinib and oral minoxidil. JAAD Case Rep. 2022;29:41\u20132.","journal-title":"JAAD Case Rep"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01723-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:31Z","timestamp":1780584811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01723-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1723"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01723-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Najwa Somani, Jakub Jedynak, Yun-Fei Chen are employees and minor shareholders of Eli Lilly and Company. Na Lu is an employee of Precision Statistics Consulting. Andrew Buchanan was an employee and minor shareholder of Eli Lilly and Company at the time of the study and is since retired. Bianca Maria Piraccini was speaker and\/or consultant for Almirall, Difa Cooper, Dercos-L\u2019Oreal, Eli Lilly, ISDIN, Legacy Healthcare, Pierre Fabre-Ducray, Giuliani, Olistic, Pfizer. Manabu Ohyama receives lecture and advisory fees from Eli Lilly Co., Pfizer Japan Inc., Maruho Co., Bristol Myers Squibb Japan, Taisho Pharmaceutical Co., AbbVie GK., Sanofi KK., Kyowa Kirin Co., Sun Pharma Japan Ltd. and ROHTO Pharmaceutical Co. and research grants not directory related with the submitted work from Maruho Co., Shiseido Co, Advantest Corp. and Sun Pharma Japan Ltd. Brett King has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator and\/or is on a Data Monitoring Committee for Abbvie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Meyers Squibb, CAGE Bio Inc, Concert Pharmaceuticals Inc, Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp, Inmagene Bio, Janssen Pharmaceuticals, LEO Pharma, Merck, Nektar, Novartis, Otsuka\/Visterra Inc, Pfizer Inc, Q32 Bio Inc, Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc, and Ventyx Biosciences Inc. He is on speaker bureaus for Abbvie, Pfizer, Regeneron and Sanofi Genzyme. He is a scientific advisor for BiologicsMD. Rodney Sinclair has been an investigator for and\/or provided professional services to AbbVie, Aerotek Scientific, Akeso Biopharma, Amgen, Arcutis, Arena Pharmaceuticals, Ascend Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Connect Biopharma, Cutanea, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, MedImmune\/AstraZeneca, Merck Sharp & Dohme, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone Biopharma, Roche, Samson Medical Technologies, Sanofi, Sun Pharma, and UCB Pharma. Maryanne M. Senna has served on scientific advisory boards for Lilly, Pfizer, Concert, Arena, Follica, Deciphera, Cassiopea; as a speaker for Lilly & Pfizer; and as principal investigator (PI) for Lilly and Concert. Rodney Sinclair is a member of the Lilly advisory board and was PI in the Lilly-sponsored BRAVE clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies adhered to the ethical standards of the Declaration of Helsinki and the Good Clinical Practice guidelines, and the research protocols were approved by the institutional review board or ethics committee at each center. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}